[Use of yasmin in the treatment of women with polycystic ovary syndrome].
OBJECTIVE
To prove the clinical efficiency over hyperandrogenism in women with PCOS after the application of the combined oral contraceptive Yasmin containing 30 mcg ethynilestradiol and 2 mg drospirenone.


METHODS
Prospective open study over 15 women taking Yasmin for six months. At the beginning and at the end of the study the following values have been checked--the Ferriman-Gallwey /F-G/ index, BMI, the waist/hip ratio (WHR), some hormonal and biochemical indexes--testosterone, SHBG, immune reactive insulin (IRI), glucose, as well as the values of free androgenic index (FAI) and insulin resistance (HOMA).


RESULTS
All fifteen women completed 6 months of therapy. The drug has been accepted very well. At the end of the study there was a significant improvement of hirsutism, expressed in the decrease of F-G index, accompanied by an increase of testosterone and SHBG values. The carbohydrate parameters haven't changed significantly.


CONCLUSIONS
Yasmin is an effective drug in the treatment of hyperandrogenism in women with PCOS with few side effects and no significant influence over insulin resistance.
Pekhlivanov
B
B
Mitkov
M
M
Ivancheva
Kh
Kh
Amaliev
I
I
D000328:Adult; D000736:Androstenes / Q000008:administration & dosage / Q000627:therapeutic use*; D015992:Body Mass Index; D004334:Drug Administration Schedule; D005260:Female; D006628:Hirsutism / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011446:Prospective Studies; D016896:Treatment Outcome; D049629:Waist-Hip Ratio
D000736:Androstenes; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone